Pomalidomide-PEG2-NH2 hydrochloride

Background Introduction

Pomalidomide-PEG2-NH2 hydrochloride is an advanced bifunctional E3 ligase ligand-linker conjugate designed for the development of next-generation PROTACs (Proteolysis Targeting Chimeras). Pomalidomide, a clinically validated immunomodulatory agent commonly used as an E3 ligase binder, is conjugated through a hydrophilic PEG2 linker with a terminal amine. This enables versatile chemical modifications and improved pharmacokinetic properties for targeted protein degradation applications.

Mechanism

This conjugate functions by recruiting the cereblon (CRBN) E3 ubiquitin ligase when incorporated into a PROTAC molecule. The pomalidomide moiety binds specifically to the CRBN E3 ligase, while the PEG2 linker provides optimal spatial orientation, solubility, and reduced steric hindrance. The terminal NH2 group serves as a reactive handle, facilitating covalent attachment to protein-of-interest (POI) ligands or other molecular modules. Once assembled into a PROTAC, the conjugate brings the target protein and E3 ligase into close proximity, promoting ubiquitination and subsequent proteasomal degradation of the POI.

Applications

Pomalidomide-PEG2-NH2 hydrochloride is widely used in PROTAC research for the synthesis of novel PROTACs aimed at targeted protein degradation. Its applications span academic and pharmaceutical settings, including the development of chemical probes, investigation of disease pathways, and drug discovery targeting oncology, neurodegenerative diseases, and other therapeutic areas where selective protein knockdown is desired. The PEG2 linker offers enhanced solubility and cell permeability, making this conjugate ideal for generating PROTACs with improved in vivo efficacy and pharmacokinetics.

Pomalidomide-PEG2-NH2 hydrochloride is a versatile E3 Ligase Ligand-Linker Conjugate that plays a crucial role in the development of PROTACs, facilitating targeted protein degradation. Its strategic design enhances the selectivity and efficiency of protein degradation, paving the way for innovative therapeutic applications. The following provides a detailed description of this molecule.

Linker: The linker in Pomalidomide-PEG2-NH2 hydrochloride is a polyethylene glycol (PEG2) chain, offering moderate length and flexibility. This enhances solubility and bioavailability while maintaining a balance between rigidity and flexibility. The linker is non-cleavable, ensuring structural stability during the degradation process.

Ligand: The ligand component is based on pomalidomide, a thalidomide derivative known for its immunomodulatory properties. Its structural configuration is optimized for binding to the cereblon E3 ligase, facilitating the recruitment of the target protein for ubiquitination and subsequent degradation.

Reactive Site: The reactive site of this molecule is the terminal amine group (NH2), which couples efficiently with the target protein ligand. Recommended reaction types include amide bond formation and nucleophilic substitution, providing robust and stable conjugation with diverse warheads.

Recommended Target Protein Ligand: The recommended warhead for this molecule is one that contains a carboxylic acid or activated ester group to react with the terminal amine. This facilitates the creation of a stable amide linkage, enhancing the specificity and potency of target protein degradation. Such warheads are advantageous for probing protein function and validating therapeutic targets in experimental studies.